Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Down 11.8% in December

Avalo Therapeutics, Inc. (NASDAQ:AVTX) saw a large drop in short interest in December. As of December 31st, there was short interest totalling 20,200 shares, a drop of 11.8% from the December 15th total of 22,900 shares. Based on an average trading volume of 84,800 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.2% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. HC Wainwright started coverage on Avalo Therapeutics in a research report on Thursday, October 24th. They issued a “neutral” rating for the company. BTIG Research started coverage on shares of Avalo Therapeutics in a research report on Thursday, December 19th. They set a “buy” rating and a $40.00 target price on the stock.

Avalo Therapeutics Stock Up 0.3 %

AVTX traded up $0.02 during midday trading on Friday, hitting $6.75. 238,024 shares of the company were exchanged, compared to its average volume of 99,375. The firm’s 50 day moving average price is $9.42 and its 200-day moving average price is $10.18. Avalo Therapeutics has a 1-year low of $4.00 and a 1-year high of $34.46.

Institutional Trading of Avalo Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AVTX. Ikarian Capital LLC boosted its stake in shares of Avalo Therapeutics by 1,673.0% in the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock valued at $9,218,000 after purchasing an additional 915,629 shares during the last quarter. RA Capital Management L.P. acquired a new position in Avalo Therapeutics in the third quarter valued at $9,186,000. Logos Global Management LP bought a new stake in Avalo Therapeutics during the second quarter valued at $6,722,000. Finally, Affinity Asset Advisors LLC grew its holdings in Avalo Therapeutics by 350.0% during the 2nd quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company’s stock worth $561,000 after acquiring an additional 35,000 shares during the period. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.